# Pathology Asia Holdings

> Pathology Asia Holdings is a VC fund backing Biopharma and Health Care. See 1 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Singapore, Singapore
- Total investments: 1
- Last investment: May 2021
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/pathology-asia/
- Website: https://www.pathologyasia.com

Pathology Asia Holdings is a medical diagnostics company that is self-contained. According to Pathology Asia, it takes a doctor to know a doctor. As a result, both doctors and corporate professionals are in charge of our medical care. Their goal is to make quality diagnostic services available to people all around Southeast Asia and beyond.

## Contacts

5 contacts available for Pathology Asia Holdings. Shizune tracks 1 team members at Pathology Asia Holdings. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/pathology-asia-holdings?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 100% |
| Health Care | 1 | 100% |
| Biotechnology | 1 | 100% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Christopher Ting | Founder & CEO | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ClearNote Health | ClearNote Health delivers epigenomic and big data approaches to reinvent non-invasive molecular diagnostic testing. The company is actively conducting multiple clinical trials to explore the efficacy of their cancer detection methods, welcoming eligible participants. The company's approach relies on epigenomics, tracking gene activity todetect changes in cells indicative of cancer. | $70M | Series C | May 12, 2021 |  |

1 of 1 investments shown.

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Pathology Asia Holdings invest in?

Pathology Asia Holdings invests primarily in Biopharma, Health Care and Biotechnology startups, most often at Series C stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Pathology Asia Holdings?

Public channels for Pathology Asia Holdings include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Pathology Asia Holdings?

The team at Pathology Asia Holdings includes Christopher Ting (Founder & CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co